The Consumer Advisor

Here are the top 10 ETF picks for August 2025, along with insights on whether they are worth considering for investment right now. This list blends global equity leaders, sector specialists in defense and metals, and broad market trackers—balancing momentum with diversification and risk management. Update: Top 10 ETF Picks for September 2025 Current market conditions and upcoming events like the U.S. Federal Reserve’s September meeting make August a timely opportunity to reallocate or accumulate: 1. SPDR S&P 500 ETF Trust (SPY) or Vanguard S&P 500 ETF (VOO) Broad U.S. equity exposure; strong performers with SPY up 8.9% YTD and focused on the AI rally and potential post-rate-cut growth ( 1 ,  2 ). Would buy: Yes, for long-term core holding and growth. 2. iShares Core S&P 500 ETF (IVV) Similar to SPY/VOO, highly liquid, low expense ratio. Would buy: Yes, for passive U.S. equity exposure ( 2 ). 3. VanEck Gold Miners ETF (GDX) or  DAXglobal Gold Miners Gol...

The stock market is closed on weekends, so the NVIDIA (NVDA) stock price on Sunday, August 31, 2025, will be the same as the closing price from the previous trading day, Friday, August 29, 2025. NVDA stock price prediction  To estimate where Nvidia stock might head by the end of August,  Finbold’s AI price prediction tool  leveraged machine learning models,  GPT-4o , Claude 3.5 Sonnet, and Grok 2 Vision, alongside a suite of technical indicators, including Moving average convergence/divergence ( MACD ), Relative Strenghth Index ( RSI ), stochastic oscillators, and 50-day moving averages (MA). According to the tool’s output, Nvidia’s share price could reach $183.17 by August 31, 2025, signaling a potential 6.18% rise from current levels. The projection spans a 30-day window from August 4 to September 15. Among the models, Claude 3.5 Sonnet gave the highest target at $188.50, implying a 9.85% increase. GPT-4o and Grok 2 Vision each estimated a price of $180, suggesting...

Merck, Roche and Celgene (now part of Bristol-Myers Squibb) have remained prominent players, but the market dynamics have shifted significantly in recent years. Aug 1, 2025 Update:  @POTUS  sent letters to 17 drug manufacturers outlining steps they must take to bring down prescription drug prices. ( source ) This increased competition is fueled by the success of blockbuster drugs like Keytruda (Merck), Tagrisso (AstraZeneca), and Ibrance (Pfizer), as well as the rapid adoption of immunotherapies and targeted treatments ( Verified Market Reports ). Look at 2017. The trio of drugmakers together held a 45.8% share of the market, with longtime cancer leader Roche controlling 26.4% all on its own. In 2024, though, market intelligence firm EvaluatePharma expects to see much more parity. The top three’s share will shrink to 26.2%, with Roche’s dropping all the way down to 11.9%. And the No. 2 through No. 5 companies—BMS, Johnson & Johnson, Pfizer, AstraZeneca and Merck—will boas...